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Commentary to “Simple prediction of long-term clinical outcomes in patients with mild 
hepatitis c recurrence after liver transplantation” 
 
Abstract 
HCV is the leading cause of death from liver disease and is the most common indication for a 
liver transplantation. Although HCV is a widespread health problem, disease management is 
particularly challenging in several key subpopulations, including liver transplant recipients. 
HCV recurrence after liver transplantation constituted a major challenge for the physicians 
during the last years. The recommended standard of care before the advent of new regimen 
was the treatment of confirmed recurrent disease, based either on persistent, unexplained 
elevated alanine aminotransferase levels or on histologically confirmed fibrosis, once 
rejection, biliary obstruction, and vascular damage have been ruled out. Moreover, early 
therapy (including interferon) has been associated with high rates of adverse effects, an 
increased risk of graft rejection, and higher proportions of patients requiring dose reductions. 
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We are now facing a “new era” of direct antiviral agents that is already changing the 
approach to HCV burden in the post liver transplantation setting.  
Available data on treatment of HCV recurrence with the new antiviral drugs showed 
sustained virological response that ranges between 60 to 100%. In this comment we have 
focused on both the utility of non invasive test to evaluate the fibrosis progression and on 
timing of antiviral therapy for HCV recurrence. 
 
The manuscript by Gambato et al. in this issue report the results from a large cohort of 
patients with mild hepatitis C (HCV) recurrence after liver transplantation (LT) followed up 
in a single referral center. The long term graft and patient survival, the progression of liver 
disease stratified by liver stiffness measurement (LSM) and the rate of cirrhosis development 
as well as the related risk factors were investigated. The Authors showed that HCV-related 
graft loss is exceptional in patients who are classified as having a mild hepatitis C. However, 
a subset of patients (15%) developed cirrhosis due to HCV progression. Donor age ≥50 years 
and AST ≥ 60 IU/L 1 year after LT were independently associated with the risk of 
progression to cirrhosis (46% at 5 after LT in case of both risk factors).  
Despite we are now facing a “new era” of direct antiviral agents (DAA) that is already 
changing the approach to HCV burden both in the pre- and in the post-LT settings, there is 
extra value by this paper. Some arguments supporting this statement are going to be 
highlighted exemplarily in the following by addressing the current state and challenges in the 
field of antiviral therapy for HCV recurrence. 
Liver transplant population has always been considered as a special population, not only 
because of SVR rates that were lower in comparison to pre-transplant setting, but also for 
other aspects (i.e.: immunosuppressive therapy, renal function, drug-drug interactions).  
During the “stone-age” combined peg-interferon (IFN) and weight-based ribavirin (RBV) 
was the standard-of-care treatment for patients with established HCV recurrence after LT (1). 
Fibrosis progression in HCV transplant recipients is associated with very early activation of 
hepatic stellate cells, a process that appears to be partially independent from necro-
inflammatory activity (2). For this reason, when to start antiviral therapy (AT) has been 
always a controversial subject. In the IFN-era, pre-emptive AT, defined as therapy started 
quite early after LT (<12 weeks) and before histological disease recurrence is present, was 
not recommended, as the efficacy has been demonstrated by several studies to be rather poor 
(3). The pre-emptive strategy, however, might eventually be used with the new-generation 
antivirals to prevent the spread out of the virus in the entire body and organs, as they are 
widely bettered tolerated compared with IFN regimen.  
 
Novel treatments for HCV infection are highly efficacious but costly. Thus, many 
insurers/drug regulation agency cover therapy only in advanced fibrosis stages.  
 
The role of liver stiffness measurement (LSM) in stratifying the risk of progression was 
considered in the paper by Gambato et al. Interestingly, in patients with mild HCV recurrence 
LSM 1 year after LT was low, but its progressive increase (slope) throughout the first 2 years 
after transplantation proved very helpful to identify individuals at risk of cirrhosis. The same 
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group (4) has previously evaluated the value of transient elastography to assess clinical 
outcomes in HCV after LT. In HCV patients, cumulative probabilities of liver 
decompensation 5 years after LT were 8% for patients with LSM <8.7 kilopascals (kPa) 
versus 47% for patients with LSM ≥ 8.7 kPa (p<0.001). Five-year graft and patient 
cumulative survival were 90% and 92% in patients with LSM<8.7 kPa (p<0.001) and 63% 
and 64% in patients with LSM ≥ 8.7 kPa, respectively (p<0.001). No association between 
outcomes and LSM at 12 months was documented in non-HCV patients. Therefore, the 
Authors conclude that LSM 1 year after LT is a valuable tool to predict HCV-related 
outcomes in recurrent hepatitis C and can be used in clinical practice to identify the best 
candidates for antiviral therapy. We certainly agree that LST could be very useful in the 
setting of HCV recurrence as non invasive tool. However, in the perspective of treating HCV 
recurrence as soon as possible, it would have been very remarkably to evaluate the impact of 
LSM increase promptly after LT (i.e.: 3 months versus 6 months after LT).  
However, it is our opinion that all patients with HCV recurrence after LT should be 
considered for AT. As a matter of fact, apart from the fact that new DAA AT are highly 
effective and extremely well tolerated, this “360°” approach for HCV recurrence is justify for 
at least two reasons.  
 
Because the two forms of severe HCV recurrence - early severe recurrent HCV, including 
FCH, and cirrhosis as a result of recurrent chronic disease more than 1 year after LT - have 
somewhat distinct clinical characteristics, as analyzed by Forns et al (5) comparing outcomes 
in these two groups of patients. In this study, patients with early recurrent hepatitis were more 
likely to achieve SVR12 (73%) than those with established cirrhosis (43%). Moreover, a 
greater proportion of patients with early recurrent hepatitis showed clinical improvement with 
respect to ascites and hepatic encephalopathy than patients with decompensated cirrhosis 
(69% vs. 45%, respectively). These results suggest that early treatment of patients with 
recurrent HCV infection after LT may offer an advantage over waiting until a patient 
develops more advanced fibrosis. However, in a simulated model (non-transplant setting) (6), 
treating HCV infection at early stages of fibrosis appeared to improve health outcomes and to 
be cost-effective but incurred substantial aggregate costs. 
 
Secondly, treating HCV infection during the first week after LT (i.e. within 30 days) could be 
useful to prevent HCV extrahepatic dissemination. It is well know that HCV infection is 
associated with injury of organs other than the liver, which is thought to contribute to 
increased rates of morbidity and all-cause mortality (7). Extrahepatic manifestations (EHMs) 
of HCV infection are variegate because they include mixed cryoglobulinemia (MC), 
lymphomas, membranous glomerulonephritis, porphyria cutanea tarda (PCT), lichen planus, 
thyroiditis, sicca syndrome, polyarthritis, diabetes mellitus (DM), cardiovascular diseases, 
and neurocognitive impairment. MC is the dominant EHM because it can be detected in half 
of all HCV-infected patients, yet less than 5% of the affected subjects develop a 
cryoglobulinemic syndrome. In this setting, early HCV eradication through AT protects 
against the clinical consequences of such EHMs as cryoglobulinemic vasculitis, 
glomerulonephritis and polyneuropathy, lymphoma, and diabetes and we think that deferral 
of HCV infection treatment favors the onset of irreversible organ injury (8). 
 
With current all oral HCV therapies, SVR rates in LT recipients appear comparable to non-
transplant patients. Table I (9-16). 
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In summary, it is important to maximize the treatment in that specific setting. Viral 
eradication post-LT to improve long-term graft and patient survival and reduce the need for 
re-LT. Our aim has to be to use the most effective treatment that provides the highest SVR 
rate. IFN-free regimens appear to be highly effective in LT recipients, therefore all patients 
should have access to AT as soon as possible, independently from fibrosis severity.  
 
Table I. “DAA in the setting of post transplant recurrence” 
Author   Drugs Genotype  Patients (n) SVR12 Notes 
Charlton M 
(9) 
SOF, LDV ± 
RBV 12 or 24 
w 
1-4 No cirrhosis (111),  
CP A (51) CP B  (52) CP 
C (9) 
FCH (6) 
Most of them previously 
treated (including PI) 
No cirrhosis 
and CP A: 
96%/98% 
CP B: 
85%/88% 
CP C: 
60%/75% 
FCH: 
100%/100%  
At baseline, 14% 
had NS5A RAV. 
Relapse occurred 
in 7% of patients 
with baseline 
RAVs as 
compared to 
4% in patients 
without. No 
relapses in 24 W 
Pungpapong 
S (10) 
SOF, SIM  
+RBV for 12 w 
(80%)  
SOF, SIM for 
12 w (20%) 
G1a: 74 
patients 
(60%) 
G1b: 43 
patients 
(35%) 
123 90% Well tolerated, 
except one death, 
possibly due to 
drug-related lung 
injury. 
Poordad F 
(11) 
SOF, DAC, 
RBV 12 w 
1 (77%) 53 
30% cirrhosis 
58%previously treated 
94% 
G1: 94%  
G3: 91% 
Among three 
patients who 
relapsed, all were 
observed to have 
NS5A variants 
Kwo P (12) Paritaprevir/r, 
dasabuvir, 
ombitasvir and 
RBV 24 w  
G1a: 29
(85%) 
G1b: 5 
(15%) 
 
Fibrosis < or equal to 2 >
12 months post-LT 
Naive 
post-transplant 
97% No death, graft 
loss or rejection 
episode. 
IS adjustment 
requested  
 
Brown SR 
(13) 
 
 
SOF, SIM  
+RBV for 12 w 
(78%)  
SOF, SIM for 
12 W (11%). 
15 pts 24 w 
G1a: 87 
(57.6%) 
G1b: 42 
(27.8%) 
151 
Treatment naïve: 66 
(43.7%) 
Priori PI failure 11 (7.3) 
88% 3 pts died due to 
aspiration 
pneumonia, 
suicide, and 
multi-organ 
failure, 1 pt 
experienced liver 
transplant 
rejection. 
Punzalan 
CS (14) 
 
SOF+SIM for 
12 w 
G1a: 33 
(79%) 
G1b: 8 
(19%) 
 
42 
Prior HCV-treatment: 
11 (26%) preOLT 
9 (21%) 
postOLT 
95% 
No 
advanced 
fibrosis: 
97% 
Advanced 
fibrosis: 
87.5% 
Adjustments  of 
FK similar to 
usual practice. 
Most patients 
(74%) tolerated 
the AT well with 
minimal side 
effects No  
rejection.  
Gutierrez 
JA (15)  
 
SOF+SIM for 
12 w 
G1a:35 
(57%) G1b: 
26 (43%) 
61 
Non responder or relapse 
to prior treatment 
93.4% 
G1b : 100%  
Incidence of AEs 
was low. No 
severe AE 
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 42 (69%)
Metavir:  
F0-F2 38 (62%) 
F3-F4 23 (38%) 
G1a: 89%. 
Metavir F3-
F4 
associated 
with 
diminished 
efficacy in 
Gt1a 
occurred.  
Saab S (16) 
 
SOF+SIM for 
12 w 
Gt1 30 patients 
Treatment naıve 10/30 
(33.3%) 
Fibrosis stage* 
0/1/2/3/4  
13 (46.4%) / 2 (7.1%) 
2 (7.7%) / 6 (23%) / 5 
(19%) 
*Two patients did not 
have biopsies. 
93% No death, graft 
loss or rejection 
episode. 
Adjustment in 
FK required in 
10 patients 
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